RUNX1 and leukemia: Topoisomerase II inhibitors are associated with another subtype of therapy-related myeloid neoplasms that emerge within 1–2 years of exposure, present as acute leukemia without antecedent MDS [220], are associated with translocations involving MLL or RUNX1 and have higher rates of response to leukemia-directed therapy [219].